Carvajal-Hausdord and colleagues applied IMC to analyze tumor tissues in trastuzumab-treated breast cancer patients: they found that the expression of HER2-extracellular segment (HER2-ECD) was reduced in relapsed patients. This evidence concerns the gene ERBB2 and neoplasm.